Business Areas

  • Development, production and marketing of chemical synthesis and biotechnological drugs, in the Latin American countries where Iclos’ commercial team is present.
  • Representation of pharmaceutical products from licensees in other areas. Oncology, hematology, nephrology, transplants, autoimmunity, and all therapeutic specialties involving state-of-the-art technologies, whether in chemical synthesis or biotechnological drugs.
  • Development, production and marketing of active pharmaceutical ingredients of biotechnological products, for companies from any continent that are interested in the development of finished products, for marketing in territories where Iclos is not present.
  • Development, production and marketing of immunosuppressants and tyrosin kinase inhibitors for countries worldwide where Iclos is not present.

Strategic Partners

CSL Behring is a leading global biotechnology company with a focus on rare and serious diseases. Its portfolio of innovative drugs includes a wide range of recombinant and plasma products to treat bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and antitrypsin alpha-1 deficiency. Iclos and CSL Behring work together in the development of blood products.

Alvogen is a global pharmaceutical company focused on the development, manufacture and sale of biosimilar drugs and products for patients around the world. It is present in more than 20 markets and its key regions are the United States, Asia, and the Pacific. Iclos works together with Alvogen in the development of monoclonal antibodies for autoimmune diseases, as well as for chemical synthesis products developed for the treatment of oncological conditions of high incidence worldwide.

EMS is the leader of the Brazilian pharmaceutical market with 100% Brazilian capitals. Its success is the result of constant investment in research and development, its modern manufacturing infrastructure, its speed and pioneering spirit in the launching of products, the synergy between the different business units, and its constant and growing focus on the innovation and talent of its employees.

Octapharma develops and produces drugs for patients in three therapeutic areas: hematology, immunotherapy, and critical care. They are present in 31 countries, with seven R&D centers and six manufacturing plants in Europe and North America.

We Produce for the World:

  • Active ingredients of biotechnology products
  • Finished products

Services to Third Parties

We have strategic alliances with companies that demand quality manufacturing for the products they are developing. We are known for our culture of service to third parties, providing services as CMO (Contract Manufacturer Organization) and strengthening partnerships with major international companies. This allows us to offer our regulatory, logistics and commercial platform for the distribution and marketing of highly qualified products in Latin America.